MiNK Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: INKT · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1840229
Sentiment: neutral
Topics: Annual Meeting, Proxy Statement, Director Election, Auditor Ratification, MiNK Therapeutics
TL;DR
<b>MiNK Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 12, 2024, to elect directors and ratify auditors.</b>
AI Summary
MiNK Therapeutics, Inc. (INKT) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. MiNK Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 12, 2024, at 9:30 AM ET. The meeting will be a live audio web conference accessible at www.virtualshareholdermeeting.com/INKT2024. Stockholders of record as of April 17, 2024, are entitled to vote. Key proposals include the election of Brian Corvese and Peter Behner as Class III directors. The appointment of KPMG LLP as the independent registered public accounting firm for fiscal year 2024 will be ratified.
Why It Matters
For investors and stakeholders tracking MiNK Therapeutics, Inc., this filing contains several important signals. This meeting is a crucial opportunity for shareholders to directly influence the company's governance by electing directors. The ratification of the independent auditor is a standard but important step in maintaining financial transparency and investor confidence.
Risk Assessment
Risk Level: low — MiNK Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Stockholders should review the director nominees and the auditor ratification proposal before the June 12, 2024 meeting.
Key Numbers
- June 12, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
- 9:30 A.M., Eastern Time — Annual Meeting Time (2024 Annual Meeting of Stockholders)
- April 17, 2024 — Record Date (Stockholders entitled to vote)
- 2027 — Director Term Expiration (Class III directors' term)
- 2024 — Fiscal Year End (Independent registered public accounting firm's fiscal year)
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- Brian Corvese (person) — Director nominee
- Peter Behner (person) — Director nominee
- KPMG LLP (company) — Independent registered public accounting firm
- Jennifer Buell, Ph.D. (person) — President and Chief Executive Officer
- AgenTus Therapeutics, Inc. (company) — Former company name
FAQ
When did MiNK Therapeutics, Inc. file this DEF 14A?
MiNK Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by MiNK Therapeutics, Inc. (INKT).
Where can I read the original DEF 14A filing from MiNK Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by MiNK Therapeutics, Inc..
What are the key takeaways from MiNK Therapeutics, Inc.'s DEF 14A?
MiNK Therapeutics, Inc. filed this DEF 14A on April 29, 2024. Key takeaways: MiNK Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 12, 2024, at 9:30 AM ET.. The meeting will be a live audio web conference accessible at www.virtualshareholdermeeting.com/INKT2024.. Stockholders of record as of April 17, 2024, are entitled to vote..
Is MiNK Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, MiNK Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading MiNK Therapeutics, Inc.'s DEF 14A?
Stockholders should review the director nominees and the auditor ratification proposal before the June 12, 2024 meeting. The overall sentiment from this filing is neutral.
How does MiNK Therapeutics, Inc. compare to its industry peers?
MiNK Therapeutics operates in the biotechnology sector, focusing on developing novel cancer immunotherapies.
Are there regulatory concerns for MiNK Therapeutics, Inc.?
This filing is a Schedule 14A (DEF 14A) under the Securities Exchange Act of 1934, requiring public companies to provide shareholders with information before their annual meetings.
Industry Context
MiNK Therapeutics operates in the biotechnology sector, focusing on developing novel cancer immunotherapies.
Regulatory Implications
This filing is a Schedule 14A (DEF 14A) under the Securities Exchange Act of 1934, requiring public companies to provide shareholders with information before their annual meetings.
What Investors Should Do
- Review the biographies and qualifications of director nominees Brian Corvese and Peter Behner.
- Understand the rationale for ratifying KPMG LLP as the independent auditor for fiscal year 2024.
- Ensure voting rights are exercised by the deadline, either by attending the virtual meeting or submitting a proxy.
Key Dates
- 2024-06-12: Annual Meeting of Stockholders — Opportunity for shareholders to vote on key proposals.
- 2024-04-17: Record Date — Determines which stockholders are eligible to vote.
- 2024-04-29: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a routine proxy statement for an annual meeting and does not contain comparative financial data from a previous filing.
Filing Stats: 4,746 words · 19 min read · ~16 pages · Grade level 9.8 · Accepted 2024-04-29 17:25:26
Key Financial Figures
- $25 billion — agement (“Chancellor”), a $25 billion money management firm. While at Chancel
Filing Documents
- 2024_proxy.htm (DEF 14A) — 650KB
- img73917039_0.jpg (GRAPHIC) — 122KB
- img73917039_1.jpg (GRAPHIC) — 116KB
- 0000950170-24-050064.txt ( ) — 979KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 14 DIRECTOR COMPENSATION 20 21 DELINQUENT SECTION 16(a) REPORTS 22 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 22 PROPOSAL 2—TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024 25 REPORT OF THE AUDIT COMMITTEE 26 ADDITIONAL INFORMATION 27 i MiNK Therapeutics, Inc. 149 Fifth Avenue, Suite 500 New York, NY 10010 Telephone: (212) 994-8250 PROXY STATEMENT April 29, 2024 This proxy statement contains information about the 2024 Annual Meeting of Stockholders of MiNK Therapeutics, Inc. (the “Annual Meeting”), including any postponements or adjournments of the meeting. The Annual Meeting will be held virtually by live audio web conference at www.virtualshareholdermeeting.com/INKT2024 on June 12, 2024 at 9:30 A.M., Eastern Time. In this proxy statement, we refer to MiNK Therapeutics, Inc. as “MiNK,” “us,” “we” or the “Company.” This proxy statement and solicitation is being made on behalf of the Board of Directors of MiNK. In accordance with the “notice and access” rules approved by the Securities and Exchange Commission (“SEC”) and in connection with the solicitation of proxies by our Board of Directors, on or about April 29, 2024 we first sent a Notice of Internet Availability of Proxy Materials and provided access to our proxy materials (consisting of this proxy statement, our Annual Report on Form 10-K for the year ended December 31, 2023 and a form of proxy) over the internet to each stockholder entitled to vote at the Annual Meeting. We intend to mail to requesting stockholders full sets of our proxy materials (consisting of this proxy statement, our Annual Report on Form 10-K for the year ended December 31, 2023 and a form of proxy) on or about April 29, 2024. Our Annual Rep